CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vanda Pharmaceuticals Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vanda Pharmaceuticals Inc.
SUITE 300E, 2200 PENNSYLVANIA AVE NW
Phone: (202) 734-3400p:202 734-3400 WASHINGTON, DC  20037  United States Ticker: VNDAVNDA
Business Summary
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Mihael H.Polymeropoulos 64 6/1/2021 5/1/2003
Chief Financial Officer, Senior Vice President, Treasurer Kevin P.Moran 40 10/26/2021 3/15/2020
Senior Vice President, Chief Marketing Officer JoakimWijkstrom 58 8/21/2019 8/21/2019
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Vanda Pharmaceuticals Germany GmbH
Vanda Pharmaceuticals GmbH
Vanda Pharmaceuticals Limited
Vanda Pharmaceuticals Netherlands B.V.
Vanda Pharmaceuticals Pte. Ltd.
VNDA

General Information
Number of Employees: 203 (As of 12/31/2023)
Outstanding Shares: 58,308,144 (As of 10/31/2024)
Shareholders: 9
Stock Exchange: NASD
Federal Tax Id: 030491827
Fax Number: (202) 296-1450


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024